ArticleBlood2005
IFN-gamma-mediated negative feedback regulation of NKT-cell function by CD94/NKG2.
Article in Blood, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 57 citations in OpenAlex.
- Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients.Mediators of inflammation · 2012Trial
- Preclinical characterization of S095029, a novel clinical-stage Fc-attenuated NKG2A-blocking antibody for cancer immunotherapy.Frontiers in oncology · 2026Article
- KLRD1 (CD94): A Prognostic Biomarker and Therapeutic Candidate in Head and Neck Squamous Cell Carcinoma.Journal of Cancer · 2025Article
- Effects of TNF-α deletion on iNKT cell development, activation, and maturation in the steady-state and chronic alcohol-consuming mice.Journal of leukocyte biology · 2022Article
- Immune profiles of male giant panda (Ailuropoda melanoleuca) during the breeding season.BMC genomics · 2021Article
- Diversity Outbred Mice Reveal the Quantitative Trait Locus and Regulatory Cells of HER2 Immunity.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Critical Contribution of NK Group 2 Member D Expressed on Invariant Natural Killer T Cells in Concanavalin A-Induced Liver Hepatitis in Mice.Frontiers in immunology · 2018Article
- IFN-γ Regulates the Expression of MICA in Human Corneal Epithelium Through miRNA4448 and NFκB.Frontiers in immunology · 2018Article
- Article
- Reconstitution models to evaluate natural killer T cell function in tumor control.Immunology and cell biology · 2016Article
- Chronic alcohol consumption enhances iNKT cell maturation and activation.Toxicology and applied pharmacology · 2015Article
- Mammalian non-classical major histocompatibility complex I and its receptors: Important contexts of gene, evolution, and immunity.Indian journal of human genetics · 2014Review
- β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Shared and distinct transcriptional programs underlie the hybrid nature of iNKT cells.Nature immunology · 2013Article
- Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer.International journal of oncology · 2012Article
- Article
- Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.European journal of immunology · 2011Article
- Diverse roles of non-diverse molecules: MHC class Ib molecules in host defense and control of autoimmunity.Current opinion in immunology · 2011Review
- NKG2A inhibits invariant NKT cell activation in hepatic injury.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Harnessing invariant NKT cells in vaccination strategies.Nature reviews. Immunology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of invariant natural killer T (iNKT) cells with CD1d-restricted T-cell receptor (TCR) ligands is a powerful means to modulate various immune responses. However, the iNKT-cell response is of limited duration and iNKT cells appear refractory to secondary stimulation. Here we show that the CD94/NKG2A inhibitory receptor plays a critical role in down-regulating iNKT-cell responses. Both TCR and NK-cell receptors expressed by iNKT cells were rapidly down-modulated by priming with alpha-galactosylceramide (alpha-GalCer) or its analog OCH [(2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-N-tetracosanoyl-2-amino-1,3,4-nonanetriol)]. TCR and CD28 were re-expressed more rapidly than the inhibitory NK-cell receptors CD94/NKG2A and Ly49, temporally rendering the primed iNKT cells hyperreactive to ligand restimulation. Of interest, alpha-GalCer was inferior to OCH in priming iNKT cells for subsequent restimulation because alpha-GalCer-induced interferon gamma (IFN-gamma) up-regulated Qa-1b expression and Qa-1b in turn inhibited iNKT-cell activity via its interaction with the inhibitory CD94/NKG2A receptor. Blockade of the CD94/NKG2-Qa-1b interaction markedly augmented recall and primary responses of iNKT cells. This is the first report to show the critical role for NK-cell receptors in controlling iNKT-cell responses and provides a novel strategy to augment the therapeutic effect of iNKT cells by priming with OCH or blocking of the CD94/NKG2A inhibitory pathway in clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.